Simpson Thacher acted as antitrust litigation counsel, settlement counsel and M&A counsel for Amedisys, Inc. in connection with the proposed settlement filed today with the U.S. District Court for the District of Maryland that will, when approved, enable Amedisys to successfully close its previously announced acquisition by UnitedHealth Group Incorporated (“UnitedHealth Group”) in a transaction valued at approximately $3.3 billion.
The proposed settlement favorably resolves claims brought by the U.S. Department of Justice (the “DOJ”) along with the Attorneys General of Maryland, Illinois, New Jersey and New York (collectively, the “States”) in connection with UnitedHealth Group’s proposed acquisition of Amedisys, consisting of (1) allegations that the transaction would harm competition for the provision of home health and hospice services, and hiring of nurses, in certain local areas, and (2) allegations that Amedisys violated Section 7A of the Clayton Act in connection with its efforts to comply with DOJ’s “Second Request.” Simpson Thacher did not represent Amedisys in connection with its response to the Second Request and was engaged after that was completed.
The settlement clears the path for Amedisys’s strategic transaction with UnitedHealth Group, which marks a significant step forward in Amedisys’s mission to expand access to high-quality, innovative home healthcare and hospice services for patients and families nationwide.
The Simpson Thacher team included Partners Sara Razi, Abram Ellis, Preston Miller, Karen Kazmerzak and Lindsey Bohl, Counsel Jared Meyer (New York), and Associates Daniel Owsley (New York), Avia Gridi, Conner Dwinell (New York), Nicholas Prendergast, Nathan May and Sophia Dillon-Davidson (Antitrust and Litigation); and Partners Jonathan Corsico and Benjamin Bodurian, and Associates Omar Kanjwal, Lawrence Ekin and Nathan Gonzalez (M&A). All attorneys are based in Washington, D.C. unless otherwise stated.